Drug intelligence / Profile preview

Reczema

Development stage: Unknown
Lead developer: Fulhold Pharma
Administration: Topical

Overview

Reczema is a CE-marked topical cream medical device developed and marketed in the EU by Fulderm Sweden for atopic dermatitis. The product is described as a Class I Medical Device under EU MDR and uses CHD-FA, a plant-derived carbohydrate-derived fulvic acid, together with skin-care excipients such as jojoba seed oil, glycerine, and linseed seed oil. Rather than acting through a defined pharmacologic receptor target, Reczema is positioned as a non-steroidal barrier-protective topical that forms a protective film over irritated skin to help protect, repair, and strengthen the skin barrier in atopic dermatitis and related eczematous or irritated skin conditions, supporting long-term use without steroids, cortisone, PEG, preservatives, or perfume.

Brand names: Reczema

Beyond the preview

Go deeper on Reczema.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reczema.

Explore the full profile